Choate Investment Advisors’s AstraZeneca AZN Stock Holding History

Choate Investment Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$870K	Sell	4,595 -92	-2%	-$17.3K	0.02%	253
2026 Q1	$923K	Buy	4,687 +345	+8%	+$66.5K	0.02%	244
2025 Q4	$798K	Sell	4,342 -812	-16%	-$142K	0.02%	251
2025 Q3	$791K	Sell	5,154 -54	-1%	-$8.17K	0.02%	232
2025 Q2	$728K	Buy	5,208 +6	+0.1%	+$841	0.02%	234
2025 Q1	$765K	Buy	5,202 +265	+5%	+$38.3K	0.02%	215
2024 Q4	$647K	Buy	4,937 +2,027	+70%	+$284K	0.02%	240
2024 Q3	$453K	Buy	2,910 +278	+11%	+$44.9K	0.01%	271
2024 Q2	$410K	Sell	2,632 -50	-2%	-$7.52K	0.01%	274
2024 Q1	$363K	Buy	2,682 +1,000	+59%	+$132K	0.01%	307
2023 Q4	$226K	Sell	1,682 -164	-9%	-$21.3K	0.01%	349
2023 Q3	$250K	Buy	1,846 +432	+31%	+$59K	0.01%	316
2023 Q2	$202K	Buy	+1,414	New	+$208K	0.01%	282

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Choate Investment Advisors's AZN Position: Q2 2026 in Review

Choate Investment Advisors reduced its AstraZeneca (AZN) stake by 2% in Q2 2026, selling an estimated $17.3K and leaving 4,595 shares worth $870K. The position accounts for 0.02% of the portfolio, ranked #253.

Choate Investment Advisors first reported a position in AZN in Q2 2023 and has held it in 13 quarters since. The position peaked at $923K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Choate Investment Advisors held 4,595 shares of AstraZeneca worth $870K as of Q2 2026.
Choate Investment Advisors sold 92 AstraZeneca shares in Q2 2026, an estimated $17.3K.
AstraZeneca made up 0.02% of Choate Investment Advisors's portfolio in Q2 2026, its #253 holding.
Choate Investment Advisors first reported a position in AstraZeneca in Q2 2023 and has held it in 13 quarters since.
Choate Investment Advisors's AstraZeneca position peaked at $923K in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Choate Investment Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.